Synapse - Renier Brentjens

Results (130)

High dose cyclophosphamide and pre-treatment disease burden dictate response and survival in a multicenter clinical trial using CD19-specific CAR T cells for relapsed/refractory B-ALL

Meeting Abstract

Curran, K. J.; Margossian, S. P.; Kernan, N. A.; Silverman, L. B.; Park, J. H.; Sauter, C. S.; Smith, E. L.; Boulad, F.; Cancio, M. I.; Forlenza, C.; more...
Blood (2017)

Fulltext@MSK | Save

Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen

Journal Article

Rafiq, S.; Purdon, T. J.; Daniyan, A. F.; Koneru, M.; Dao, T.; Liu, C.; Scheinberg, D. A.; Brentjens, R. J.
Leukemia (2017)

Fulltext@MSK | Save

Durable long-term survival of adult patients with B-ALL after CD19 CAR (19-28z) T cell therapy

Meeting Abstract

Park, J.; Riviere, I.; Wang, X.; Senechal, B.; Wang, Y.; Purdon, T.; Brentjens, R.; Sadelain, M.
Haematologica (2017)

Fulltext@MSK | Save

Baseline and early post-treatment clinical and laboratory factors associated with severe neurotoxicity following 19-28z CAR T cells in adult patients with relapsed B-ALL

Meeting Abstract

Park, J.; Riviere, I.; Wang, X.; Senechal, B.; Wang, Y.; Santomasso, B.; Sadelain, M.; Brentjens, R.
Haematologica (2017)

Fulltext@MSK | Save

A Phase I trial of 19-28z CAR-T cells post-high dose therapy and autologous transplantation (HDT-ASCT) for relapsed and refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL)

Meeting Abstract

Sauter, C.; Riviere, I.; Senechal, B.; Ni, A.; Bernal, Y.; Wang, X.; Purdon, T.; Hall, M.; Moskowitz, C.; Giralt, S.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save

Disease burden and transplant on long-term survival after CD19 CAR T cells in adults with relapsed acute lymphoblastic leukemia

Meeting Abstract

Park, J.; Rivere, I.; Wang, X. Y.; Senechal, B.; Curran, K.; Sauter, C.; Wang, Y. Z.; Li, D.; Brentjens, R.; Sadelain, M.
Molecular Therapy (2017)

Fulltext@MSK | Save

Impact of disease burden on long-term outcome of 19-28z CAR modified T cells in adult patients with relapsed B-ALL

Meeting Abstract

Park, J. H.; Riviere, I.; Wang, X.; Purdon, T.; Sadelain, M.; Brentjens, R. J.
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

Updated results: Phase I trial of autologous CD19-targeted CAR T cells in patients with residual CLL following initial purine analog-based therapy

Meeting Abstract

Geyer, M. B.; Park, J. H.; Riviere, I.; Wang, X.; Purdon, T.; Sadelain, M.; Brentjens, R. J.
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

Implications of concurrent ibrutinib therapy on CAR T-cell manufacturing and phenotype and on clinical outcomes following CD19-targeted CAR T-cell administration in adults with relapsed/refractory CLL